SCHEMBL2072872

SCHEMBL2072872

CC(=O)SCCN1C(=O)CC[C@@H]1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 1/20 0.31
▸ DUT P33316 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24795959 0.83 PDK2 (0.41) FKBP1ADUT
SCHEMBL1401084 0.83 PDK2 (0.41) FKBP1ADUT
SCHEMBL27650285 0.82 PTGER4 (0.39) FKBP1A
SCHEMBL959434 0.81 FKBP1A (0.32) FKBP1A
SCHEMBL959880 0.81 FKBP1A (0.34) FKBP1ADUT
SCHEMBL28526467 0.80 DUT (0.33) DUT
SCHEMBL2850230 0.80 DUT (0.33) DUT
SCHEMBL21389332 0.80 DUT (0.33) DUT
SCHEMBL24795965 0.80 DUT (0.33) DUT
SCHEMBL10210244 0.80 PTGER4 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130143934-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES ONO PHARMACEUTICAL CO., LTD. (JP) 2013-06-06 — — US disclosed
US-8404858-B2 Agent for regeneration and/or protection of nerves ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-26 — — US disclosed
US-20120202773-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 — — US disclosed
US-8207223-B2 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 — — US disclosed
US-20110059920-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES ONO PHARMACEUTICAL CO., LTD (JP) 2011-03-10 — — US disclosed
US-7863263-B2 Agent for regeneration and/or protection of nerves ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-04 — — US disclosed
US-20100010222-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 — — US disclosed
US-7608637-B2 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 — — US disclosed
US-20090227644-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES ONO PHARMACEUTICAL CO., LTD (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143934-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES PTGER3, PTGER2, PTGER1 FKBP1A 3356/4885DUT 4259/4885
US-20120202773-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT PTGER4, PTGER1, PTGER2 FKBP1A 2110/4885DUT 3019/4885
US-20090227644-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES PTGER3, PTGER2, PTGER1 FKBP1A 3356/4885DUT 4259/4885
US-20110059920-A1 AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES PTGER3, PTGER2, PTGER1 FKBP1A 3356/4885DUT 4259/4885
US-20100010222-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT PTGER4, PTGER1, PTGER2 FKBP1A 2110/4885DUT 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback